Table 1 Characteristics of eligible studies.
Study | Latest update | Type of trial (registry number) | Enrollment period | Age range (year) | Chemo-regimen-Control arm-Platinum arm | TNBC NO.-Control-Platinum | Carboplatin dosage | TNM stage | Stage of therapy | Median follow-up | HR (95% CI) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DFS | OS | |||||||||||
CALGB 40603 | 2015 | RCT(NCT00861705) | 2009.5−2012.8 | 18–70 | −P/PB*12w-4ddAC−P/PBCb*12w-4ddAC | −212−221 | AUC 6, d1, q3w | Stage II/III | Neoadjuvant | 39m | 0.84 (0.58−1.22) | 1.15 (0.74–1.79) |
Khalid | 2015 | RCT(NS) | 2008.1−2014.12 | 17–65 | −3CEF-3T−3CEF-3TCb-1yCM | −80−78 | AUC 5, d1, q3w | Stage II/III;T > 1 cm/LN+ | Adjuvant | 52m | 0.61 (0.39–0.96) | 0.56 (0.32–0.98) |
Zhang | 2016 | RCT(NS) | 2006.5−2012.12 | 24–73 | −4-6EP−4-6PCb | −44−47 | AUC 5, d1, q3w | Stage II/III | Neoadjuvant | 55m | 0.56 (0.25–1.27) | 0.70 (0.22–2.26) |
GeparSixto | 2018 | RCT(NCT01426880) | 2011.8−2012.12 | 48 | −PM*18w+Beva−PMCb*18w+Beva | −157−158 | AUC 1.5/2, d1, qw | Stage II/III | Neoadjuvant | 47.3m | 0.56 (0.34–0.93) | 0.60 (0.32–1.12) |
PATTERN | 2020 | RCT(NCT01216111) | 2011.6−2016.4 | 18–70 | −3CEF-3T-6PCb | −322−325 | AUC 2, d1, 8, 15, q28d | N1-3, or T1c-4aN0, M0 | Adjuvant | 62m | 0.65 (0.44–0.96) | 0.71 (0.42–1.22) |
Du | 2020 | RCT(NS) | 2009.7−2015.10 | 48 | −4EC-4T-6TCb | −154−154 | AUC 5, d1, q3w | N1-3, or T1c-4aN0, M0 | Adjuvant | 66.9m | 1.11 (0.65–1.89) | 1.27 (0.49–3.32) |
Iwase | 2020 | RCT(UMIN000003355) | 2010.3−2011.9 | 47 (30–70) | −3T-3CEF-3TCb-3CEF | −38−37 | AUC 5, d1, q3w | Stage II/III A | Neoadjuvant | 6.6y | 0.22 (0.06–0.82) | 0.12 (0.01–0.96) |
